PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Retatrutide Versus Tirzepatide in T2DM: Indirect Network Meta-Analysis of Sparse Data

retatrutidetirzepatidedulaglutideGIPGLP-1glucagon receptor agonistincretintype 2 diabetes mellitusnetwork meta-analysissystematic reviewweight lossHbA1c Endocrinology / Diabetes / Obesity

Background Information

Retatrutide outperforms in weight reduction for diabetes management.

Type 2 diabetes mellitus often requires enhanced glycemic control strategies, making novel agents like retatrutide highly relevant. Retatrutide 8 mg significantly reduced body weight (-13.03 kg) and waist circumference (-8.63 cm), with both agents improving HbA1c and fasting insulin levels. The findings suggest that retatrutide may offer superior weight loss benefits compared to existing treatments, but further clinical adoption requires more direct comparative studies. Retatrutide shows promise for enhanced weight management in type 2 diabetes compared to current incretin therapies.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Tereshchenko A, Garay Gálvez B, Tello JA

Citation: Tereshchenko A, Garay Gálvez B, Tello JA Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus. Therapeutic advances in endocrinology and metabolism. 2026;19:20420188261474093. doi:10.1177/20420188261474093

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.